Page last updated: 2024-12-08
hycanthone methanesulfonate
Description
hycanthone methanesulfonate: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
hycanthone mesylate : A methanesulfonate salt resulting from the reaction of equimolar amounts of hycanthone and methanesulfonic acid. It was formerly used as a schistosomicide for individual or mass treatement of infection with Schistosoma haematobium and S. mansoni, but due to its toxicity and concern about possible carcinogenicity, it has been replaced by other drugs such as praziquantel. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 285666 |
| CHEMBL ID | 1983709 |
| CHEBI ID | 24624 |
| SCHEMBL ID | 1152656 |
| MeSH ID | M0041507 |
Synonyms (27)
| Synonym |
|---|
| etrenol |
| hycanthone methanesulphonate |
| hycanthone monomethanesulphonate |
| hycanthone mesylate |
| thioxanthen-9-one, monomethanesulfonate (salt) |
| 9h-thioxanthen-9-one, monomethanesulfonate (salt) |
| hycanthone methane sulfate |
| 23255-93-8 |
| hycanthone methanesulfonate |
| nsc142982 , |
| hycanthone monomethanesulfonate |
| C19432 |
| CHEMBL1983709 |
| CCG-35909 |
| 48830nw22a , |
| CHEBI:24624 , |
| n,n-diethyl-2-{[4-(hydroxymethyl)-10-oxo-10h-dibenzo[b,e]thiopyran-1-yl]amino}ethanaminium methanesulfonate |
| 1-{[2-(diethylamino)ethyl]amino}-4-(hydroxymethyl)-10h-dibenzo[b,e]thiopyran-10-one methanesulfonate |
| hycanthone monomesylate |
| hycanthone mesylate [iarc] |
| hycanthone mesylate [hsdb] |
| hycanthone mesylate [mi] |
| 9h-thioxanthen-9-one, 1-((2-(diethylamino)ethyl)amino)-4-(hydroxymethyl)-, methanesulfonate (1:1) |
| SCHEMBL1152656 |
| Q27109846 |
| 1-[2-(diethylamino)ethylamino]-4-(hydroxymethyl)thioxanthen-9-one;methanesulfonic acid |
| n-[2-(diethylamino)ethyl]-4-methoxy-9-oxoxanthene-1-aminemonomethanesulphonate |
Roles (3)
| Role | Description |
|---|
| alkylating agent | Highly reactive chemical that introduces alkyl radicals into biologically active molecules and thereby prevents their proper functioning. It could be used as an antineoplastic agent, but it might be very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. It could also be used as a component of poison gases. |
| mutagen | An agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution. |
| schistosomicide drug | Drugs that used to treat infestations by flukes (trematodes) of the genus Schistosoma. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
| Class | Description |
|---|
| methanesulfonate salt | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |